糖尿病性心不全の疫学を探る

2型糖尿病 (T2D) と心不全 (HF) はどちらも増加する一方で、今や「蔓延」の域に達しようとしています。心不全 コーヴァンス これは双方の疾患が生理学的に関係していることを考えればまったく不思議ではありません。どちらも高齢者に多く、不摂生な食事や座ったままで動くことの少ないライフスタイルなどが関係しています。 しかし、本質的な糖尿病性心筋症の存在や、糖尿病で心不全が多発するケースが一般的な併発状態(冠動脈疾患や動脈高血圧症)によるものなのかといった点をめぐっては、未だに議論が続いており、 いずれにせよ双方の疫学は平行線をたどっています。米国では現在、65 歳以上の患者様の退院時の診断として心不全が最も多く、この年齢層の約 25% が T2D を抱えています。

Understanding the Definitions

HF, which is a clinical syndrome and not a specific disease, is generally defined as the inability of the heart to support the body’s metabolic demands. This results in symptoms such as fatigue, shortness of breath and/or leg swelling. While related, the syndrome of HF and the diagnosis of cardiomyopathy are not the same thing. “Cardiomyopathy” means that the ventricular muscle (“myo”) is diseased (“pathy”) unrelated to coronary artery disease. Not all patients with cardiomyopathy have HF symptoms particularly if their disease is in the early stages or there are adequate compensatory physiologic mechanisms to elude the symptoms.

HFpEF, HFrEF and Diabetes

In the general population, about 40-50% of patients with HF actually have intact systolic function (squeeze) of the main pumping chamber of the heart, the left ventricle (LV). In these patients the LV ejection fraction (percentage of blood volume ejected with each beat) appears normal on imaging studies and thus, at least on the surface, the LV, seems to squeeze well. This type of HF is termed HF with preserved ejection fraction or HFpEF. In HFpEF, the LV walls are generally thickened and the chamber is small and stiff leading to increased internal pressures and a blunting of the normal increase in cardiac output associated with exercise. In contrast, in patients with HF with reduced ejection fraction (HFrEF) the LV is enlarged and baggy with walls that are thin or normal in thickness and the squeeze of the pumping chamber is reduced.

The prevalence of HFpEF appears to be increasing in an absolute sense but also relative to HFrEF which was previously considered the most common form of HF. While the split is not well-documented, it appears that at least as many diabetic patients with HF suffer from HFpEF compared to HFrEF. However, there is growing concern that the prevalence of HFpEF in diabetic patients may be considerably higher than this and surpass that in the non-diabetic population. For example, in the Rotterdam Study, the HFpEF to HFrEF ratio was as high as four to one.1 Thus, in considering therapeutic approaches to the diabetic heart, the underlying pathophysiology of HFpEF must be strongly considered.

Prevalence of Diabetes in Patients with Heart Failure

The precise prevalence of diabetes in patients with HF is not well-documented. In our review of relatively recent heart failure trials, the prevalence of T2D ranged from 28-39% with a higher prevalence noted in HFrEF-based studies.2, 3 However, the population statistics of clinical trials do not always mirror the general patient population and the actual prevalence of T2D in community-based HF patients may vary a bit from this number.

Prevalence of Heart Failure in Diabetic Patients

About 10-15% of patients with T2D patients have underlying HF4 and the presence of T2D is a risk for future HF presentations. In the well-known Framingham Heart Study, a long-standing epidemiologic investigation of a free-living, non-hospitalized population, the incidence of HF over time was 2.4 times greater in diabetic men and 5 times greater in diabetic women compared to their non-diabetic counterparts.5

As the population ages, HF incidence increases in both diabetic and non-diabetic populations which results in blunting of the difference in HF prevalence between these two groups. In a study of over 8,000 diabetic patients, when compared to their non-diabetic counterparts, the odds ratio for prevalent HF was 11.0 in patients under 45 years of age which dropped to 1.8 in subjects aged 75-84.4 Other comorbidities associated with ageing in both populations may result in the evening out of HF prevalence in the two groups of patients.

Nevertheless, the combination of diabetes and aging remain powerful risk factors for HF and, in the Cardiovascular Health Study, the HF incidence in diabetics over the age of 65 was still two times greater than in the non-diabetic population.7 In the Rotterdam Study, at least 40% of elderly diabetic patients had a heart failure diagnosis.1

Subclinical Cardiomyopathy in Diabetics

The availability of noninvasive imaging tools such as echocardiography and magnetic resonance imaging have made it possible to detect subclinical evidence of diabetes-related changes in cardiac morphology and function. The NIH-sponsored Multi-Ethnic Study of Atherosclerosis (MESA) study evaluated 4,991 subjects without known, preexisting cardiac disease. When compared to non-diabetic controls, researchers noted modest thickening (hypertrophy) of the LV walls in patients who had elevated fasting glucose levels – a finding that was even greater in known diabetics.6 Subclinical functional abnormalities such as reduction in global LV strain, a subtle marker of heart muscle squeeze, have also been documented in almost 50% of diabetics without who have no history or symptoms of HF.8,9

Possible Ethnic or Genetic Predisposition to Diabetic Cardiomyopathy

Ethnicity-specific differences are another interesting angle to examine in the epidemiology of diabetic HF. In the MESA study mentioned above, where LV hypertrophy was observed in the overall population of diabetics, when adjustment was made for age and body size, hypertrophy was observed only in black and Hispanic subjects. These results suggest that there may be an ethnic or genetic predisposition to diabetic cardiomyopathy or at least myocyte responsiveness to chronic hyperinsulinemia.6

Prognostic Effect of Diabetes in Heart Failure Patients

The combination of diabetes and HF conveys a poor prognosis. In the Swedish Heart Failure Registry of over 35,000 patients, diabetes was associated with a 37% increase in mortality and this increase was observed across all age groups.10

要旨

The epidemiologic link between diabetes and HF is clear suggesting a pathophysiologic relationship between the two conditions. This evidence suggests that more aggressive, targeted management of these patients, including closer monitoring at the subclinical cardiomyopathic stage, may be warranted. The earlier inclusion of drugs in the diabetic regimen associated with lower HF risk such as the SGLT2 antagonists may also  be indicated in high risk patients though this remains to be confirmed in prospective clinical trials. For further discussion of mechanisms and current treatment options, please watch the Covance webinar: The Diabetic Heart: A Focus On Heart Failure

Read more in the next series of this blog: Untangling the Mechanisms of the Diabetic Heart


参照

  1. Mosterd A et al. Prevalence of heart failure and left ventricular dysfunction in the general population: The Rotterdam Study. Eur Heart J (1999) 20(6):447-455.
  2. Konstam MA et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. (2007) 297(12):1319-31.
  3. Massie BM et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. (2008) 359:2456-67.
  4. Nichols GA et al. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care (2001) 24:1614-1619.
  5. Kannel WB et al. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. (1974) 34:29-34.
  6. Bertoni AG et al. Diabetic cardiomyopathy and subclinical cardiovascular disease: the multi-ethnic study of atherosclerosis (MESA). Diabetes Care (2006) 29(3):588-594.
  7. Gottdiener JS et al. Predictors of congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol. (2000) 35:1628-37.
  8. Holland DJ et al. Subclinical LV dysfunction and 10-year outcomes in type 2 diabetes mellitus. Heart (2014) 101:1061-66.
  9. Nakai H et al. Subclinical left ventricular dysfunction in asymptomatic diabetic patients assessed by two-dimensional speckle tracking echocardiography: correlation with diabetic duration. Eur J Echocardiogr. (2009) 10:926-32.
  10. Johansson I et al. Is the prognosis in patients with diabetes and heart failure a matter of unsatisfactory management? An observational study from the Swedish Heart Failure Registry. Eur J Heart Fail. (2014) 16:409-18.